Estudo de Fase II do Uso da Associação de Interferon Alfa e Isotretinoína no Tratamento de Tumores Sólidos Avançados

Authors

  • André M. Murad Faculdade de Medicina. Universidade Federal de Minas Gerais (UFMG). Belo Horizonte (MG), Brasil
  • Tânia M. Saldanha Serviço de Hematologia e Oncologia. Hospital das Clínicas. Universidade Federal de Minas Gerais (UFMG) Belo Horizonte (MG), Brasil
  • CLÁUDIA H. Alves Serviço de Hematologia e Oncologia. Hospital das Clínicas. Universidade Federal de Minas Gerais (UFMG) Belo Horizonte (MG), Brasil
  • Maria L. P. Freitas Serviço de Hematologia e Oncologia. Hospital das Clínicas. Universidade Federal de Minas Gerais (UFMG) Belo Horizonte (MG), Brasil

DOI:

https://doi.org/10.32635/2176-9745.RBC.1995v41n1.2911

Keywords:

Interferon, Retinoic Acid, Cervical Cancer, Head and Neck Cancer, Kaposi's Sarcoma

Abstract

Some pre-clinical and clinical data support the efficacy and synergism of the combination of retinoids and interferons in the treatment of several so!id tumors. In this prospective phase II trial, thirty patients with advanced and refractoty so!id fumors received interferon alpha-2a, 6 MU/m2 subcutaneously dailay, 5 days a week and 13-cis-retinoic acid, 1 mg/kg orally, daily, for at Ieast 2 months, depending on the response or toxicity. Eighteen had squamous cell cervical carcinoma; 6, squamous cell carcinoma of head and neck; 5, Kaposi'sarcoma already refractory to interferon therapy and 1, xeroderma pigmentosum and several basaloid and squamous cell carcinoma of the skin. There were 5 (16.6%) objective responses, includíng 4 partial responders and 1 complete responder. Additionally, there were 4 disease stabilization. No patient with Kaposi's sarcoma has responded. Median time to progression was 6 months (range 3-11). Toxicity was very mild and mana geable, including Iow fever, fatigue, dry skin and mialgia. These results are encouraging and the use of such a combination as an initial treatment of squamous cell tumors, mainly in neoadjuvant setting is warranted

Downloads

Download data is not yet available.

References

SMITH TJ, HILLNEA BE, DESCH CE. Efficacy and cost-effectiveness in oncology: rational allocation of cancer care resources. J Nati Cancer inst 85:1460-1474, 1993 DOI: https://doi.org/10.1093/jnci/85.18.1460

ANTMAN KH, SOUHAMI RL. High-dose chemotherapy in solidtumors. Ann Oncol 4 (suppi 1): S29-S44, 1993 DOI: https://doi.org/10.1093/annonc/4.suppl_1.S29

GALLAGHER R, LURKE K, LEAVITT et al. Effects of interferon and retinoic acid on the growth and differentiation of cionogenic Leukemia celis. Leuk Res 7:609-619, 1987 DOI: https://doi.org/10.1016/0145-2126(87)90033-6

SCHINDLER C. Interferon-dependent tyrosine phosphorilation of a latent cytoplasmatic transcriptor factor. Science 257:809-813, 1992 DOI: https://doi.org/10.1126/science.1496401

SM1TH MA, PARKINSON DR, CHESON BD et al: Retinoids in cancer therapy. J Chn Oncol 1992; 10:837-862. DOI: https://doi.org/10.1200/JCO.1992.10.5.839

LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA M et al. 13-cis-retinoic acid plus interferon alpha 2-a in Iocally advenced squamous cell carcinoma of the cervix. J Nati Cancer Inst 85;499-500, 1993 DOI: https://doi.org/10.1093/jnci/85.6.499

LIPPMAN SM, PARKINSON DR, ItriLMetai. 13-cis-retinoic acid plus interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin.J Nati Cancer inst 44: 235-241, 1992 DOI: https://doi.org/10.1093/jnci/84.4.235

KROWN SE. Phase I Study of lFN-A/TRA in patients with AlDS- Associated kaposi's sarcoma - MSKCC trial # 92062A2, 1994

PARKINSON DR, SMiTH MA, CHESON BD et al. Transretinoic acid and related differentiating agents. Sem Oncol 19:734-741, 1992

MILLER AB. Reporting results of câncer treatment. Cancer 47:207-214, 1981 DOI: https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

FLETCHER R.H.; FLETCHER S.W.; WAGNER E.H. - Clinícal epidemiology, the essentials, 2. ed. Philadeiphia. Williams & Wilkins, 1988 p.82

KAPLAN E.L. & MEIER P.- Nonparametric estimation fron incomplete observations. J. Am Stat Assoc. 53: 457-481, 1958. DOI: https://doi.org/10.1080/01621459.1958.10501452

CAMPOS-FILHO N. & FRANCO E.L.F - Microcomputer-assisted univariate survi vai data analysis using Kaplan-Meier life table estimators. Comp Meth Prog Biomed 27: 223-228, 1988. DOI: https://doi.org/10.1016/0169-2607(88)90086-7

WAXMAN S. The status of differentiation Therapy. Raven Press, New York, 1988.

ROMNEY SL, PALAN PR, DATTAGUPTA C et al. Retinoids in the prevention of cervical dysplasias. Am. J. Obstet. Gynecol. 141:890, 1991 DOI: https://doi.org/10.1016/S0002-9378(16)32680-1

STONE A MAYER R. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 8:1913-1921, 1990 DOI: https://doi.org/10.1200/JCO.1990.8.11.1913

CLEAVER JE. Defectivo repair replication of DNA in xeroderma pigmentosum. Nature 218:652, 1968 DOI: https://doi.org/10.1038/218652a0

MURAD AM, OLIVEIRA MA, SALDANHA TM. Phase II trial ofisotretinoin and interferon-alpha in the treatment of advanced recurrent cervical carcinoma. int J Gynecol cancer 4: 441-418,1994 DOI: https://doi.org/10.1046/j.1525-1438.1994.04060414.x

Published

2023-06-02

How to Cite

1.
Murad AM, Saldanha TM, Alves CH, Freitas MLP. Estudo de Fase II do Uso da Associação de Interferon Alfa e Isotretinoína no Tratamento de Tumores Sólidos Avançados. Rev. Bras. Cancerol. [Internet]. 2023 Jun. 2 [cited 2024 Nov. 25];41(1):7-14. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/2911

Issue

Section

ORIGINAL ARTICLE